-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text|Pharmaceutical Mission Hills
Recently, Haichuang Pharmaceuticals announced that the company has introduced a potential "first-in-class" new drug under development from Germany's amcure GmbH, the clinical trial application of HP558 injection has been formally approved by the National Food and Drug Administration (NMPA) of China Accept
.
HP558 is an inhibitor that specifically targets CD44v6 and has completed phase 1 clinical trials in Europe
CD44v6 is a splice variant of the CD44 family of transmembrane glycoproteins.
It is involved in many processes related to tumor progression, including epithelial mesenchymal transition (EMT), cell migration and invasion
.
HP558 can block the signal transduction of the three tyrosine kinases VEGFR-2, c-MET and RON by binding to CD44v6, thereby strongly inhibiting the growth and metastasis of squamous cell tumors
Preclinical and clinical trials have shown that HP558 has good anti-tumor activity, safety and tolerability, and has potential therapeutic effects in gastrointestinal tumors
.
At the same time, it can also be used in combination with chemotherapy or other targeted drugs, which is expected to treat a variety of advanced tumors
▲The mechanism model of HP558 (picture source: amcure GmbH official website)
In November 2020, Haichuang Pharmaceutical obtained the exclusive license rights for the development and commercialization of all indications of HP558 in China (including Hong Kong, Macao and Taiwan)
.
The acceptance of this clinical application is an important progress made by Haichuang Pharmaceutical in China after the introduction of this new drug under development
Haichuang Pharmaceutical is an innovative drug company based on technology platforms such as deuterium and PROTAC, with the goal of developing best-in-class and first-in-class drugs with significant clinical needs
.
The company focuses on the research and development of innovative drugs in major therapeutic areas such as tumors and metabolic diseases, focusing on providing patients with safe, effective and affordable drugs, and is committed to the development and production of innovative drugs with global rights
Reference materials:
[1] amcure and Hinova Pharmaceuticals enter into an exclusive license agreement for the development, manufacturing and commercialization of AMC303 in oncology in the Greater China region.
